India, June 3 -- Johnson & Johnson (JNJ) shared new findings at the 2025 ASCO Annual Meeting from two Phase 3 studies, PERSEUS and CEPHEUS, highlighting the long-term benefits of a DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen in newly diagnosed multiple myeloma (NDMM) patients, regardless of transplant eligibility.
In the PERSEUS study (Abstract #7501), transplant-eligible patients who received DARZALEX FASPRO with bortezomib, lenalidomide, and dexamethasone (D-VRd), followed by investigational maintenance with DARZALEX FASPRO and lenalidomide (D-R), showed significantly improved rates of minimal residual disease (MRD) negativity at 10?5 sensitivity. Over 50 percent of patients achieved sustained MRD negati...